Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12602-021-09773-9 http://scihub22266oqcxt.onion/10.1007/s12602-021-09773-9 33770348!7996120!33770348     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Probiotics+Antimicrob+Proteins 2021 ; 13 (5): 1239-1253 Nephropedia Template TP {{tp|p=33770348|t=2021. The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development |pdf=|usr=}}{{33770348}} gab.com Text The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development JO: Probiotics Antimicrob Proteins http://www.kidney.de/pget.php?&tw=1&pmid=33770348 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing the 2019 novel coronavirus disease (COVID-19), was introduced by WHO (World Health Organization) as "pandemic" in March 2020. According to WHO, thus far (23 November 2020) 58,425,681 infected cases including 1,385,218 deaths have been reported worldwide. In order to reduce transmission and spread of this lethal virus, attempts are globally being made to develop an appropriate vaccine. Intending to neutralize pathogens at their initial entrance site, protective mucosal immunity is inevitably required. In SARS-CoV2 infection and transmission, respiratory mucosa plays a key role; hence, apparently mucosal vaccination could be a superior approach to elicit mucosal and systemic immune responses simultaneously. In this review, the advantages of mucosal vaccination to control COVID-19 infection, limitations, and outcomes of mucosal vaccines have been highlighted. Considering the gut microbiota dysregulation in COVID-19, we further provide evidences on utilization of recombinant probiotics, particularly lactic acid bacteria (LAB) as vaccine carrier. Their intrinsic immunomodulatory features, natural adjuvanticity, and feasible expression of relevant antigen in the mucosal surface make them more appealing as live cell factory. Among all available platforms, bioengineered probiotics are considered as the most affordable, most practical, and safest vaccination approach to halt this emerging virus. Twit Text FOAVip The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development ????Probiotics Antimicrob Proteins http://www.kidney.de/pget.php?&tw=1&pmid=33770348 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33770348 #FOAvip English Wikipedia <ref>{{Cite pmid|33770348}}</ref> The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development #MMPMID33770348 Moradi-Kalbolandi S; Majidzadeh-A K; Abdolvahab MH; Jalili N; Farahmand L Probiotics Antimicrob Proteins 2021[Oct]; 13 (5): 1239-1253 PMID33770348show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing the 2019 novel coronavirus disease (COVID-19), was introduced by WHO (World Health Organization) as "pandemic" in March 2020. According to WHO, thus far (23 November 2020) 58,425,681 infected cases including 1,385,218 deaths have been reported worldwide. In order to reduce transmission and spread of this lethal virus, attempts are globally being made to develop an appropriate vaccine. Intending to neutralize pathogens at their initial entrance site, protective mucosal immunity is inevitably required. In SARS-CoV2 infection and transmission, respiratory mucosa plays a key role; hence, apparently mucosal vaccination could be a superior approach to elicit mucosal and systemic immune responses simultaneously. In this review, the advantages of mucosal vaccination to control COVID-19 infection, limitations, and outcomes of mucosal vaccines have been highlighted. Considering the gut microbiota dysregulation in COVID-19, we further provide evidences on utilization of recombinant probiotics, particularly lactic acid bacteria (LAB) as vaccine carrier. Their intrinsic immunomodulatory features, natural adjuvanticity, and feasible expression of relevant antigen in the mucosal surface make them more appealing as live cell factory. Among all available platforms, bioengineered probiotics are considered as the most affordable, most practical, and safest vaccination approach to halt this emerging virus. |*Immunity, Mucosal[MESH] |Animals[MESH] |COVID-19 Vaccines/administration & dosage/genetics/*immunology[MESH] |COVID-19/*immunology/microbiology/prevention & control/virology[MESH] |Drug Development[MESH] |Gastrointestinal Microbiome[MESH] |Gene Expression[MESH] |Humans[MESH] |Lactobacillales/*genetics/immunology[MESH]The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 V(epmc).pdf DeepDyve Pubget Overpricing